Ryan Witt serves as VP of Business Development of Spinogenix, where he leads the company’s partnering activities. In addition, Ryan is Vice President and Head of Strategy and Business Development at Nasdaq-listed RenovoRx, a drug-device combination product company with its latest asset in a phase 3 clinical trial. 

Previously, he was the Chief Operating Officer of Immix Biopharma where he took the company from preclinical to human trials and a Nasdaq offering. Ryan has a BA in business economics with a minor in biological sciences from the University of California, Irvine.